Cingulate Inc. (CING)

NASDAQ: CING · Real-Time Price · USD
4.940
-0.230 (-4.45%)
At close: Sep 18, 2024, 4:00 PM
4.980
+0.040 (0.81%)
After-hours: Sep 18, 2024, 7:59 PM EDT
-4.45%
Market Cap 10.77M
Revenue (ttm) n/a
Net Income (ttm) -19.10M
Shares Out 2.18M
EPS (ttm) -24.46
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 252,941
Open 5.070
Previous Close 5.170
Day's Range 4.850 - 5.230
52-Week Range 1.800 - 187.200
Beta -0.89
Analysts Buy
Price Target 96.00 (+1,843.32%)
Earnings Date Nov 11, 2024

About CING

Cingulate Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company’s stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults. It also focuses on developing CTx-21... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Dec 8, 2021
Employees 13
Stock Exchange NASDAQ
Ticker Symbol CING
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for CING stock is "Buy." The 12-month stock price forecast is $96.0, which is an increase of 1,843.32% from the latest price.

Price Target
$96.0
(1,843.32% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Cingulate Initiates Final Study for Lead ADHD Asset CTx-1301

$10 Million of additional Capital Recently Raised Strengthening Balance Sheet $10 Million of additional Capital Recently Raised Strengthening Balance Sheet

6 days ago - GlobeNewsWire

Cingulate to Participate in Benzinga All Live Access Event

KANSAS CITY, Kan., Aug. 27, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technol...

22 days ago - GlobeNewsWire

Cingulate Announces Adjournment of Special Meeting

KANSAS CITY, Kan., Aug. 23, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), (“Cingulate” or the “Company”), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™)...

26 days ago - GlobeNewsWire

Cingulate stock surges 115% after European patent approval for ADHD treatment: Is it a buy?

Cingulate Inc (NASDAQ: CING), a biopharmaceutical firm specializing in innovative ADHD treatments, experienced a remarkable surge in its stock price on Friday, with shares skyrocketing by 115%. This d...

4 weeks ago - Invezz

Cingulate Issued European Patent for Lead Asset CTx-1301 for the Treatment of ADHD

KANSAS CITY, Kan., Aug. 15, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technol...

4 weeks ago - GlobeNewsWire

Cingulate Reports Second Quarter 2024 Financial Results and Provides Development Update on Major Milestones Achieved

FDA Clears Cingulate to File for Marketing Approval of CTx-1301 targeted in 1H 2025 Licensing Activity Continues

5 weeks ago - GlobeNewsWire

Cingulate Announces Exercise of Warrants for $1.86 Million Gross Proceeds

KANSAS CITY, Kan., June 28, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (the “Company”) (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery ...

2 months ago - GlobeNewsWire

Cingulate and ADHD Expert Dr. Ann Childress, MD to Participate in Benzinga All Live Access Event

KANSAS CITY, Kan., June 25, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technol...

3 months ago - GlobeNewsWire

Cingulate Achieves Key Manufacturing Milestone in the Development of its ADHD Drug CTx-1301 in Preparation for FDA Marketing Clearance

Twelve Required Registration Batches Completed New Drug Application Being Prepped for Submission KANSAS CITY, Kan., June 25, 2024 (GLOBE NEWSWIRE) -- In alignment with U.S. Food and Drug Administratio...

3 months ago - GlobeNewsWire

Cingulate Reports First Quarter 2024 Financial Results and Provides Clinical and Business Update

CTx-1301 on track to file for Marketing Approval with FDA in 1H 2025 Increase of $10 Million in Stockholders' Equity KANSAS CITY, Kan., May 08, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), ...

4 months ago - GlobeNewsWire

Peter J. Werth, Successful Pharma Entrepreneur, Philanthropist, Cingulate Investor and Board Member, to be Featured with Chairman and CEO Shane J. Schaffer on Benzinga All Live Access

KANSAS CITY, Kan., April 30, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform techno...

5 months ago - GlobeNewsWire

Cingulate to Participate in Planet MicroCap Showcase: Vegas 2024

KANSAS CITY, Kan., April 16, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform techno...

5 months ago - GlobeNewsWire

Cingulate Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Clinical and Business Update

$17.8 Million Raised Since Beginning of 2023 $9.1 Million of Debt Converted to Equity at a Premium Phase 3 ADHD Data Continues to Impress

6 months ago - GlobeNewsWire

Cingulate to Attend DCAT Week 2024 in New York City

Will Host Licensing Meetings with Multiple Parties to Discuss Assets, Pipeline and Technology Will Host Licensing Meetings with Multiple Parties to Discuss Assets, Pipeline and Technology

7 months ago - GlobeNewsWire

Cingulate Appoints Jay Roberts, Bryan Lawrence, and Jeff Ervin to its Board of Directors

Announcement Follows Recent Public Offering and Successful Capital Raising Activity Announcement Follows Recent Public Offering and Successful Capital Raising Activity

7 months ago - GlobeNewsWire

Cingulate Announces Closing of $7.5 Million Public Offering

KANSAS CITY, Kan., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING) (“Cingulate,” the “Company,” “we,” “our” or “us”), a biopharmaceutical company utilizing its proprietary Precision Ti...

8 months ago - GlobeNewsWire

Cingulate Announces Pricing of $7.5 Million Public Offering

KANSAS CITY, Kan., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING) (“Cingulate,” the “Company,” “we,” “our” or “us”), a biopharmaceutical company utilizing its proprietary Precision Ti...

8 months ago - GlobeNewsWire

Longtime Cingulate Controller Jennifer Callahan Promoted to CFO

KANSAS CITY, Kan., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc.  (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform techno...

8 months ago - GlobeNewsWire

Werth Family Investment Associates Converts Remaining $3.3M of Debt and Accrued Interest into Cingulate Equity at Premium to Market

KANSAS CITY, Kan., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING) (Cingulate), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery plat...

8 months ago - GlobeNewsWire

Cingulate's stock skyrockets again, as ADHD treatment developer as delisting is delayed pending a February hearing

Shares of Cingulate Inc. CING, +101.52% blasted 226.3% higher in premarket trading Thursday after the biopharmaceutical company disclosed that the delisting of its stock has been delayed until at leas...

9 months ago - Market Watch

Cingulate Receives Guidance from FDA on Path Forward for Anxiety Asset CTx-2103 (buspirone)

KANSAS CITY, Kan., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technol...

10 months ago - GlobeNewsWire

Cingulate Inc. Reports Third Quarter 2023 Financial Results and Provides Clinical and Business Update

Phase 3 Adult Efficacy and Safety Trial Data Presented at Psych Congress  Cingulate Closed a $4M Public Offering  $5.8M of Debt Converted into CING Equity

11 months ago - GlobeNewsWire

Cingulate to Host CNS Key Opinion Leader Panel in New York City

Expert Analysis of Cingulate, its Phase 3 ADHD Adult Data, Anxiety, and PTR™ Drug Delivery Platform Innovations Expert Analysis of Cingulate, its Phase 3 ADHD Adult Data, Anxiety, and PTR™ Drug Delive...

1 year ago - GlobeNewsWire

Cingulate Inc. to Present at the LD Micro Main Event XVI

KANSAS CITY, Kan., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technol...

1 year ago - GlobeNewsWire

Cingulate Inc. To Present at the LD Micro Main Event XVI

Presentation on Wednesday, October 4th at 02:30 PM PT Kansas City, Kansas--(Newsfile Corp. - September 21, 2023) - Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary ...

1 year ago - Newsfile Corp